BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

Historically, optic nerve involvement has been excluded from MS diagnostic criteria, but its inclusion in the new iteration ...

A growing body of evidence is shifting expert opinion toward supporting MS treatment during pregnancy, emphasizing ...

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...

This was the stock's third consecutive day of losses.

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $121.00. The company’s shares closed y ...

Biogen has highlighted the growing role of felzartamab in its pipeline during a virtual investor seminar, spotlighting three ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $175.00. The company’s shares closed today at $133.06.

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...